The launch of AMILI Metabolic Health, a novel synbiotic product, marks a significant step in addressing the unique metabolic health needs of Asian populations. This groundbreaking product, developed in collaboration with Unity and Singapore's National University Hospital (NUH), leverages the distinct gut microbiome characteristics of Asians, particularly those from Singapore. The product's formulation is a testament to the importance of using data from diverse, multi-ethnic Asian populations to create targeted health solutions.
A Data-Driven Approach
The development of AMILI Metabolic Health is grounded in a comprehensive understanding of the Asian gut microbiome. The product's formulation is based on data from NUH, which includes microbiome profiles of patients with conditions like hypertension and hyperlipidemia, as well as healthy individuals who have undergone AMILI's gut microbiome testing. This dual-source data approach allows for a nuanced understanding of the microbial interactions and their impact on metabolic health.
Dr. Jeremy Lim, co-founder and CEO of AMILI, emphasizes the significance of Asian-specific data in product development: "An Asian gut is not the same as a Western one. The microbes are primarily driven by our diets, lifestyles, and environment, which is why solutions built on Asian data matter." This statement underscores the importance of tailoring health solutions to the unique characteristics of the Asian population.
A Unique Formulation
The AMILI R&D team has crafted a formulation containing four probiotic strains, including Lactobacillus rhamnosus, Bifidobacterium animalis subsp. lactis, Lactobacillus plantarum, and Bifidobacterium adolescentis, along with the postbiotic Akkermansia, prebiotic fiber, and botanical extracts like milk thistle. Each ingredient is carefully selected to address specific metabolic health concerns.
For instance, Lactobacillus rhamnosus is designed to improve fasting blood glucose, liver function, reduce insulin resistance, and alleviate liver stress and inflammation. Akkermansia, on the other hand, targets insulin sensitivity, total cholesterol, and body composition. The optimal dose and proportion of these strains were determined using an AI model, ensuring the product's efficacy and safety.
Validating Efficacy
The formulation's efficacy was rigorously validated against NUH's patient cohort, with glycemic, lipid, and hepatic endpoints as primary objectives. These endpoints include body mass index (BMI), HbA1C, LDL-cholesterol, ALT/AST, and fibrosis scores. Additionally, the prebiotics and postbiotics' efficacy was validated using AMILI's functional microbiota assay, an ex vivo gut model using Asian stool donors.
Metabolic Health: A Focused Approach
The choice of metabolic health as the primary focus for this R&D process is not arbitrary. It is a significant health challenge among Asians, and an area where there is a clear opportunity to develop products tailored to the specific needs of the Asian population. Dr. Lim highlights the importance of this approach, noting that even the World Health Organization recognizes the lower BMI thresholds for obesity and overweight in Asians compared to Western populations.
A Collaborative Effort
The collaboration between AMILI, Unity, and NUH exemplifies the power of combining clinical insights from Singaporean patients with microbiome science. Associate Professor Dan Yock Young, a senior consultant at the National University Centre for Digestive Health at NUH, emphasizes the impact of this collaboration: "Collaborations that combine clinical insights from Singaporean patients with microbiome science help deepen our understanding of how the gut microbiome may influence health and disease, and can contribute to the development of new approaches to support metabolic health in Asian populations."
Conclusion: A Step Towards Asian Metabolic Health
The launch of AMILI Metabolic Health is a significant milestone in the pursuit of improving metabolic health in Asian populations. By leveraging the unique characteristics of the Asian gut microbiome and collaborating with leading institutions, AMILI is setting a new standard for targeted health solutions. This product not only addresses a critical health need but also highlights the importance of data-driven, culturally relevant approaches in the development of healthcare products.
